Our recent studies also supported the notion that early adaptive precision drug-resistant escape in EGFR-mutant NSCLC under EGFR inhibitor treatment is associated with a quiescence cell state under transcriptomic-metabolomic cellular reprogramming that has an enhanced EMT-ness, cancer stemness, and upregulated vimentin (Thiagarajan et al. 2016). This evidence concerns the gene EGFR and non-small cell lung carcinoma.